Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Melanoma diagnosis: traumatic impact of the event on the patient.

Campolmi E, Riccio M, Carli B, Bacci G, Pino MS, Fortunato S, Gunnella S, Fioretto L, Borgognoni L, Pimpinelli N.

G Ital Dermatol Venereol. 2019 Jun 12. doi: 10.23736/S0392-0488.19.06348-X. [Epub ahead of print]

PMID:
31195781
2.

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.

Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M.

Clin Cancer Res. 2019 Apr 9. doi: 10.1158/1078-0432.CCR-19-0311. [Epub ahead of print]

PMID:
30967421
3.

Enhancement and modeling of enzymatic hydrolysis on cellulose from agave bagasse hydrothermally pretreated in a horizontal bioreactor.

Pino MS, Rodríguez-Jasso RM, Michelin M, Ruiz HA.

Carbohydr Polym. 2019 May 1;211:349-359. doi: 10.1016/j.carbpol.2019.01.111. Epub 2019 Feb 8.

PMID:
30824099
4.

Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes.

Scarpi E, Dall'Agata M, Zagonel V, Gamucci T, Bertè R, Sansoni E, Amaducci E, Broglia CM, Alquati S, Garetto F, Schiavon S, Quadrini S, Orlandi E, Casadei Gardini A, Ruscelli S, Ferrari D, Pino MS, Bortolussi R, Negri F, Stragliotto S, Narducci F, Valgiusti M, Farolfi A, Nanni O, Rossi R, Maltoni M; Early Palliative Care Italian Study Group (EPCISG).

Support Care Cancer. 2019 Jul;27(7):2425-2434. doi: 10.1007/s00520-018-4517-2. Epub 2018 Oct 24.

PMID:
30357555
5.

Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).

Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, Gori S, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentini S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E; NICSO (Network Italiano per le Cure di Supporto in Oncologia).

Support Care Cancer. 2019 Mar;27(3):1041-1047. doi: 10.1007/s00520-018-4393-9. Epub 2018 Aug 6.

PMID:
30084104
6.

Multicentric study of the effect of pre-analytical variables in the quality of plasma samples stored in biobanks using different complementary proteomic methods.

Mateos J, Carneiro I, Corrales F, Elortza F, Paradela A, Del Pino MS, Iloro I, Marcilla M, Mora MI, Valero L, Ciordia S, Fernández V, Fortuño MA, García-Sánchez I, Martínez R, Muñoz MA, Rodriguez C, Doménech N; ProteoRed Spanish Biobanks Network.

J Proteomics. 2017 Jan 6;150:109-120. doi: 10.1016/j.jprot.2016.09.003. Epub 2016 Sep 9.

PMID:
27620695
7.

Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.

Montagnani F, DI Leonardo G, Pino MS, Martella F, Perboni S, Ribecco A, Fioretto L.

Anticancer Res. 2016 Aug;36(8):4259-65.

PMID:
27466541
8.

Genetic mechanisms in interval colon cancers.

Richter JM, Pino MS, Austin TR, Campbell E, Szymonifka J, Russo AL, Hong TS, Borger D, Iafrate AJ, Chung DC.

Dig Dis Sci. 2014 Sep;59(9):2255-63. doi: 10.1007/s10620-014-3134-2. Epub 2014 Apr 5.

PMID:
24705641
9.

On the regioselectivity of the mononuclear copper-catalyzed cycloaddition of azide and alkynes (CuAAC). A quantum chemical topological study.

Calvo-Losada S, Pino MS, Quirante JJ.

J Mol Model. 2014 Apr;20(4):2187. doi: 10.1007/s00894-014-2187-7. Epub 2014 Mar 25.

PMID:
24664121
10.

Adrenomedullin is a therapeutic target in colorectal cancer.

Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC.

Int J Cancer. 2014 May 1;134(9):2041-50. doi: 10.1002/ijc.28542. Epub 2013 Nov 7.

11.

Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

Ribecco AS, Pino MS, Cipriani G, Marinozzi C, Fioretto L.

Expert Rev Anticancer Ther. 2013 Oct;13(10):1181-91. doi: 10.1586/14737140.2013.837667. Review.

PMID:
24134420
12.

Severe thrombocytopenia after trastuzumab retreatment: a case report.

Pino MS, Angiolini C, Fioretto L.

BMC Res Notes. 2013 Oct 4;6:400. doi: 10.1186/1756-0500-6-400.

13.

Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice.

Arnason T, Pino MS, Yilmaz O, Kirley SD, Rueda BR, Chung DC, Zukerberg LR.

Cancer Biol Ther. 2013 Jul;14(7):672-8. doi: 10.4161/cbt.25089. Epub 2013 May 31.

14.

A changing landscape in castration-resistant prostate cancer treatment.

Felici A, Pino MS, Carlini P.

Front Endocrinol (Lausanne). 2012 Jul 18;3:85. doi: 10.3389/fendo.2012.00085. eCollection 2012.

15.

Proteomic analysis of the pinworm Syphacia muris (Nematoda: Oxyuridae), a parasite of laboratory rats.

Sotillo J, Trelis M, Cortés A, Valero ML, del Pino MS, Guillermo Esteban J, Marcilla A, Toledo R.

Parasitol Int. 2012 Dec;61(4):561-4. doi: 10.1016/j.parint.2012.05.004. Epub 2012 May 11.

PMID:
22583759
16.

Molecular and genetic bases of pancreatic cancer.

Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Milella M.

Curr Drug Targets. 2012 Jun;13(6):731-43. Review.

17.

Emerging pathways and future targets for the molecular therapy of pancreatic cancer.

Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M.

Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Review.

PMID:
21819318
18.

Development of a human extracellular matrix for applications related with stem cells and tissue engineering.

Escobedo-Lucea C, Ayuso-Sacido A, Xiong C, Prado-López S, del Pino MS, Melguizo D, Bellver-Estellés C, Gonzalez-Granero S, Valero ML, Moreno R, Burks DJ, Stojkovic M.

Stem Cell Rev. 2012 Mar;8(1):170-83. doi: 10.1007/s12015-011-9270-6. No abstract available.

19.

Microsatellite instability in the management of colorectal cancer.

Pino MS, Chung DC.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):385-99. doi: 10.1586/egh.11.25. Review.

PMID:
21651356
20.

Application of molecular diagnostics for the detection of Lynch syndrome.

Pino MS, Chung DC.

Expert Rev Mol Diagn. 2010 Jul;10(5):651-65. doi: 10.1586/erm.10.45. Review.

21.

Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells.

Zeng M, Kikuchi H, Pino MS, Chung DC.

PLoS One. 2010 Jun 4;5(6):e10966. doi: 10.1371/journal.pone.0010966.

22.

The chromosomal instability pathway in colon cancer.

Pino MS, Chung DC.

Gastroenterology. 2010 Jun;138(6):2059-72. doi: 10.1053/j.gastro.2009.12.065. Review.

23.

Proteomic analysis of in vitro newly excysted juveniles from Fasciola hepatica.

Hernández-González A, Valero ML, del Pino MS, Oleaga A, Siles-Lucas M.

Mol Biochem Parasitol. 2010 Aug;172(2):121-8. doi: 10.1016/j.molbiopara.2010.04.003. Epub 2010 Apr 18.

PMID:
20403391
24.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

Milella M, Gelibter AJ, Pino MS, Bossone G, Marolla P, Sperduti I, Cognetti F.

Oncologist. 2010;15(2):e1-4. doi: 10.1634/theoncologist.2008-0135.

25.

Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability.

Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY, Iafrate AJ, Zukerberg LR, Chung DC.

Gastroenterology. 2010 Apr;138(4):1406-17. doi: 10.1053/j.gastro.2009.12.010. Epub 2009 Dec 21.

26.

Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.

Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC.

Cancer Res. 2009 Nov 1;69(21):8499-506. doi: 10.1158/0008-5472.CAN-09-2213. Epub 2009 Oct 20.

27.

Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas.

Pino MS, Mino-Kenudson M, Wildemore BM, Ganguly A, Batten J, Sperduti I, Iafrate AJ, Chung DC.

J Mol Diagn. 2009 May;11(3):238-47. doi: 10.2353/jmoldx.2009.080142. Epub 2009 Mar 26.

28.

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.

Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P, Cognetti F.

Oncology. 2009;76(4):254-61. doi: 10.1159/000205388. Epub 2009 Feb 26.

PMID:
19246950
29.

Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.

Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P.

Clin Cancer Res. 2008 Aug 1;14(15):4943-50. doi: 10.1158/1078-0432.CCR-08-0436.

30.

A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).

Pino MS, Gamucci T, Mansueto G, Trapasso T, Narducci F, Giampaolo MA, Fariello AM, Sperduti I, Ceribelli A, Cognetti F.

Lung Cancer. 2008 Jun;60(3):381-6. Epub 2007 Dec 19.

PMID:
18068853
31.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma.

Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G.

Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. Review.

PMID:
17594187
32.

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.

Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D.

Cancer. 2007 Aug 1;110(3):525-33.

33.

Gender differences: implications for clinical trials and practice.

Ceribelli A, Pino MS, Cecere FL.

J Thorac Oncol. 2007 May;2(5 Suppl):S15-8. Review. No abstract available.

34.

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.

Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ.

Cancer Res. 2007 Feb 15;67(4):1430-5.

35.

Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.

Ceribelli A, Pino MS, Gelibter AJ, Milella M, Cecere FL, Caterino M, Facciolo F, Mirri A, Cognetti F.

Cancer. 2007 Feb 15;109(4):727-31.

36.

Molecular correlates of gefitinib responsiveness in human bladder cancer cells.

Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ.

Mol Cancer Ther. 2007 Jan;6(1):277-85.

37.

Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?

Ferretti G, Felici A, Pino MS, Cognetti F.

J Clin Oncol. 2006 Dec 1;24(34):5469-70; author reply 5470-1. No abstract available.

PMID:
17135653
38.

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ.

Mol Cancer Ther. 2006 Sep;5(9):2251-60.

40.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.

41.

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3773-81.

42.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, Pino MS, Carlini P, Di Cosimo S, Sacchi I, Sperduti I, Nardoni C, Cognetti F.

Ann Oncol. 2006 Apr;17(4):630-6. Epub 2006 Jan 12.

PMID:
16410363
43.

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ.

Cancer Res. 2005 Dec 15;65(24):11658-66. Erratum in: Cancer Res. 2009 Feb 15;69(4):1695.

44.

Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells.

Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ.

Cancer Biol Ther. 2005 Nov;4(11):1263-9. Epub 2005 Dec 1.

PMID:
16319525
45.

Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.

Fabi A, Papaldo P, Pino MS, Ferretti G, Carlini P, Pacetti U, Di Cosimo S, Nardoni C, Giannarelli D, Sacchi I, Cognetti F.

Anticancer Res. 2004 May-Jun;24(3b):1963-7.

46.

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.

Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F.

Ann Oncol. 2003 Sep;14(9):1378-82.

PMID:
12954576
47.

[Capecitabine in the treatment of colorectal cancer].

Zeuli M, Pino MS, Cognetti F.

Tumori. 2001 Jan-Feb;87(1 Suppl 1):S55-6. Italian. No abstract available.

PMID:
11300027

Supplemental Content

Support Center